ESMO 2021 | Highlights in glioblastoma at ESMO 2022

Maximilian Mair, MD, Medical University of Vienna, Vienna, Austria, shares his highlights in glioblastoma from the European Society for Medical Oncology (ESMO) 2022 Congress. Encouraging early phase data was presented with an IDO inhibitor, as well as on the combination of retifanlimab with bevacizumab and hypofractioned irradiation. At ESMO 2021, preclinical data was shown on the synergistic activity of L19TNF plus lomustine in murine mouse models. This year, data was presented on the Phase I GLIOSTRA (NCT04573192) study of L19TNF plus lomustine in patients with glioblastoma at first progression, demonstrating promising progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.